IBB: Beyond The 2025 Surge, Biotech Breakout
Source: SeekingAlpha
2026-01-27 05:10:39 ET
After a multi-year drought, the iShares Biotechnology ETF ( IBB ) has been quietly having a fantastic run, returning about 28% for 2025, dwarfing its modest returns in 2023, alongside losses in 2022, 2024, amid a renewed risk appetite, a healthy environment of IPO & M&A activity, alongside a sturdy show by large-cap biotechs, where IBB derives its weights from....
Read the full article on Seeking Alpha
For further details see:
IBB: Beyond The 2025 Surge, Biotech Breakout
SPDR Series Trust S&P Biotech
NASDAQ: XBI
XBI Trading
-0.93% G/L:
$121.85 Last:
5,802,368 Volume:
$123.43 Open:
XBI Latest News
November 17, 2025 09:18:00 pm
Biotech Insiders Are Spending Billions. Trump Favors Less Oversight. One Biotech ETF Could Ride the Surge.
